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In this issue of Critical Care, Dale Rublee and colleagues
look beyond 28-day all-cause mortality, assessing the effects
of antithrombin III on quality of life in sepsis survivors [1].
Although many of us would like to think that the battle has
been won when a patient leaves the intensive care unit (ICU)
after severe sepsis or acute respiratory distress syndrome
(ARDS), a growing body of literature indicates that survivors
of intensive care have an increased risk of death and have a
significantly impaired quality of life after they leave the ICU.
There are several possible mechanisms for these long-term
effects, and many patients may be affected by several of
them. Survival may be impaired simply because people with
severe co-morbid diseases are most likely to get critically ill.
Alternatively, critical illness may leave patients
immunosuppressed and at risk for further complications that
lead to early death. Hypoxemia, septic encephalopathy, and
sedative medication may cause cognitive dysfunction [2].
Critical illness neuromyopathy, steroids, and bedrest may
cause profound weakness [3]. The trauma of critical illness
and false memories may cause post-traumatic stress disorder
and depression [4]. Financial burdens continue well after
hospital discharge [5]. Tracheostomy scars, striae from
anasarca, decubitus ulcers, and digits lost to ischemia may
affect patients’ self image.
The study by Rublee and colleagues [1] is an analysis of
secondary endpoints in the Kybersept (antithrombin III) trial
that failed to show a statistically significant effect on 28-day
mortality [6]. They compared the Karnofsky performance scale
and six domains of a visual analogue scale of quality of life:
mobility, physical activity, communications–speech, alertness,
energy, and overall quality of life. The authors performed at
least 63 statistical comparisons across variables, time points,
and populations to identify several situations in which
antithrombin III seemed to have a statistically significant effect
on quality of life. It is difficult to assess the importance of this
effect because the clinically significant difference in
percentage change in their visual analogue scale is unknown.
Because the results are all expressed as change from a
baseline assessment when the patients were critically ill, we
cannot tell their actual status at each time point. Despite these
limitations, this study raises several important questions that
critical care investigators must answer as we design studies
of quality of life after critical illness.
What do differences in quality of life after
critical illness mean?
Physicians treat angina and asthma to improve patients’
quality of life. We do not expect therapy for severe sepsis to
improve patients’ quality of life; at best we hope to return
patients to their pre-morbid health status [7]. Ideally, we can
find management techniques that minimize the effects of a
critical illness on long-term quality of life. Conflicts may arise
between treatments that are life-saving and those that affect
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Abstract
A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It
is not entirely clear from the available literature whether this impairment is a complication of critical
illness or a complication of therapy. There is little evidence to guide physicians to treatments in the
intensive care unit that will minimize the effects of critical illness on these sequelae. Although the study
by Rublee and colleagues in this issue of Critical Care provides little clinically useful information about
the effects of antithrombin III on quality of life, it provides some insight into the challenges that
investigators will encounter as we try to incorporate these outcomes into studies of critical illness.
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quality of life after critical illness. For example, it is possible
that lung-protective ventilation for ARDS using increased
sedation, lower oxygenation, and permissive hypercapnea
saves lives but leads to worse cognitive function than a
strategy using large tidal volume oriented toward normoxia
and eucapnea [2,8]. There are as yet insufficient data to
assess this trade-off [8]. Functional status and quality of life
are extremely important to patients’ decisions about life-
sustaining treatment, and much better data are needed to
allow us to predict future health status [9].
How should informative censoring be analyzed?
Dead people do not contribute data to studies of quality of
life. When death competes with a non-mortality endpoint
such as quality of life, a phenomenon called ‘informative
censoring’ can occur. A treatment that increases mortality
may preferentially lead to the death of debilitated patients
who would have had very poor quality of life if they had
survived. Similarly, a treatment that saves the lives of very ill
debilitated patients may rescue these patients so that they
are healthy enough to contribute very poor quality-of-life data
to the study. Life-saving therapy in the ICU can seem to
worsen quality of life, and harmful treatments can seem to
improve quality of life. It is therefore problematic to adopt a
therapy in the ICU solely on the basis of its apparent effect
on quality of life unless we know that this effect is not
purchased by increasing mortality in the most debilitated.
There are statistical techniques for studying a non-mortality
endpoint in the face of competing mortality and these should
be used by intensivists to evaluate the effects of interventions
on quality of life after critical illness [10,11].
Which outcome measures should be used?
Intensivists are used to attempts in the complex body of
literature in critical care to identify the ‘best’ severity of illness
measure [12]. A similar, even more extensive, body of
literature exists that explores the ‘best’ quality-of-life
instruments [13]. Entire journals are devoted to these
questions. There is no single perfect instrument to measure
all aspects of health status. Experts debate the
responsiveness, validity, clinical significance, and
practicability of these instruments in various patient
populations. Selecting a general measure-of-health status
that has been used extensively, such as the SF (Short Form)-
36 or EuroQOL, allows investigators to compare their results
with a mature database of patients with many different
diseases. Studying measures of function, for example muscle
strength, cognitive ability, and psychiatric status, can provide
invaluable information for understanding the mechanisms of a
reduced health-related quality of life. Investigators interested
in establishing the cost-utility of a therapy should use a health
status measure that can be converted to patient utilities.
Where do we go from here?
Reducing the long-term impairment associated with critical
illness presents a set of new challenges to clinicians in the
ICU. We need more information on the natural history of
functional impairment after critical illness. We need
association studies that link factors before, during, and after
treatment in the ICU with health status. Continuing clinical
trials in critical care can provide this information on risk
factors by including long-term follow-up for survival and
quality of life in their data collection. In the very near future
we should expect clinical trials exploring the effects of ICU
and post-ICU interventions targeted at improving quality of
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